ライフサイエンスコーパス: meropenem

1 o carbapenem antibiotics (either imipenem or meropenem).

2 of fosfomycin in conjunction with high-dose meropenem.

3 le in MacConkey broth containing 1 mug/ml of meropenem.

4 vents were probably or definitely related to meropenem.

5 Ala (acylenzyme) mutants with the carbapenem meropenem.

6 for polymyxin B, tigecycline, cefepime, and meropenem.

7 logue and (ii) the carbapenems, imipenem and meropenem.

8 ity with carbapenems, including imipenem and meropenem.

9 d on ImiS and its reaction with imipenem and meropenem.

10 to increase in resistance of the bacteria to meropenem.

11 ells than did PBP 3-specific ceftriaxone and meropenem.

12 IC, < = or 4 micrograms/ml) was proposed for meropenem.

13 Intravenous meropenem (1 g every 8 hours) and moxifloxacin (400 mg e

14 Interventions: Meropenem (1 g intravenously every 8 hours) or placebo w

15 plus metronidazole (500 mg) every 8 hours or meropenem (1 g) every 8 hours intravenously for 4-14 day

16 nd nosocomial SBP were randomized to receive meropenem (1 g/8 hours) plus daptomycin (6 mg/kg/day) or

17 em, 0.5%, 8%, 78%; imipenem, 1, 16, 75%; and meropenem, 1, 16, 82%.

18 ipenem, 1, 8, 69%; imipenem, 2, 16, 67%; and meropenem, 1, 32, 70%; and by nonintensive care units: D

19 ients were randomized to receive intravenous meropenem (1000 mg) every 8 hrs and 107 patients were ra

20 went skin tests with imipenem/cilastatin and meropenem; 130 of them were skin-tested also with ertape

21 re nonsusceptible to chloramphenicol (5.7%), meropenem (16.6%), and cefotaxime (11.8%).

22 High-level resistance was detected for meropenem (2 strains) and trimethoprim-sulfamethonazole

23 wed by ciprofloxacin (32.6%) and imipenem or meropenem (28.7%).

24 ility in trough concentrations (6.7-fold for meropenem, 3.8-fold for piperacillin, 10.5-fold for tazo

25 rog/ml versus 16 microg/ml); and similar for meropenem (4 micro g/ml versus < or = 1 microg/ml), cipr

26 l that, in the SFC-1 acylenzyme complex, the meropenem 6alpha-1R-hydroxyethyl group interacts with As

27 regimens achieved target concentrations for meropenem (89%), piperacillin (83%), and vancomycin (60%

28 gecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates we

29 hich was further enhanced when combined with meropenem, a common anti-Pseudomonal carbapenem antibiot

30 resistant strains in adjunctive therapy with meropenem, a standard-of-care antibiotic, confirming the

31 s nitrocefin and cefaclor and the carbapenem meropenem, a substantial quench of fluorescence is obser

32 bactam plus metronidazole was noninferior to meropenem across all primary analysis populations.

33 bsiella pneumoniae, AMA efficiently restored meropenem activity, demonstrating that a combination of

34 The structures of apo-LdtMt5 and its meropenem adduct presented here demonstrate that, despit

35 AMA also fully restored the activity of meropenem against Enterobacteriaceae, Acinetobacter spp.

36 ned meropenem and moxifloxacin compared with meropenem alone did not result in less organ failure.

37 (8.3 points; 95% CI, 7.8-8.8 points) and the meropenem alone group (7.9 points; 95% CI, 7.5-8.4 point

38 and moxifloxacin (400 mg every 24 hours) or meropenem alone.

39 ere tested for their capability to hydrolyze Meropenem, an FDA-approved carbapenem drug.

40 firmed necrotizing pancreatitis: 50 received meropenem and 50 received placebo.

41 e criteria for testing H. influenzae against meropenem and ampicillin should maximize reference test

42 The combination of meropenem and ciprofloxacin was predominantly additive o

43 The combinations meropenem and ciprofloxacin, meropenem and teicoplanin,

44 Meropenem and clavulanate are Food and Drug Administrati

45 The sensitivity and specificity of meropenem and ertapenem for carbapenemase activity among

46 f.), and two Vitek cards (GNS-116 containing meropenem and GNS-F7 containing imipenem) (bioMerieux Vi

47 itute (CLSI) lowered the MIC breakpoints for meropenem and imipenem from 4 mg/liter to 1 mg/liter for

48 e sensitive indicator of KPC resistance than meropenem and imipenem independently of the method used.

49 Meropenem and imipenem provided high probabilities of ac

50 A dose-ranging study with meropenem and levofloxacin alone and in combination agai

51 Meropenem and levofloxacin penetrations into epithelial

52 Meropenem and levofloxacin were administered to partiall

53 with severe sepsis, treatment with combined meropenem and moxifloxacin compared with meropenem alone

54 nt difference in mean SOFA score between the meropenem and moxifloxacin group (8.3 points; 95% CI, 7.

55 in 26% (13 of 50) and 20% (10 of 50) of the meropenem and placebo groups, respectively (P = 0.476).

56 re (MacConkey broth containing 1 mg/liter of meropenem and subcultured to a MacConkey agar plate with

57 he combinations meropenem and ciprofloxacin, meropenem and teicoplanin, moxifloxacin and teicoplanin,

58 OXA-24/40 with close to the same affinity as meropenem and undergoes a complete catalytic hydrolysis

59 The patient was treated empirically with meropenem and vancomycin, and the fever resolved within

60 13 for isolates that were not susceptible to meropenem and/or imipenem.

61 muM for moxifloxacin, 43.6 +/- 10.7 muM for meropenem, and 7.1 +/- 0.6 muM for piperacillin) and in

62 sivist-led model of care, the empiric use of meropenem, and adjunctive treatment with granulocyte col

63 introduction of an intensivist-led service, meropenem, and adjuvant granulocyte colony-stimulating f

64 rium acnes ophthalmic isolates to ertapenem, meropenem, and cefepime by utilizing the Etest.

65 d 1 microg/ml to 12 microg/ml for ertapenem, meropenem, and cefepime, respectively.

66 obacter baumannii by BOCILLIN FL, aztreonam, meropenem, and ceftazidime.

67 ssfully treated with vancomycin, tobramycin, meropenem, and clindamycin is described.

68 next showed that the carbapenems (imipenem, meropenem, and doripenem) form long-lived acyl-enzyme in

69 tient was shown to be resistant to imipenem, meropenem, and ertapenem by disk diffusion susceptibilit

70 nd/or OXA carbapenemases, by using imipenem, meropenem, and ertapenem with LC-MS/MS assays.

71 hat other beta-lactams, such as cephalothin, meropenem, and penicillin G, proceed through an electron

72 sis and septic shock, that is, moxifloxacin, meropenem, and piperacillin in aqueous solution and huma

73 azolin, ciprofloxacin, colistin, gentamicin, meropenem, and tetracycline in comparison to the results

74 ent bolus dosing of piperacillin-tazobactam, meropenem, and ticarcillin-clavulanate conducted in 5 in

75 lities to piperacillin-tazobactam, imipenem, meropenem, and trovafloxacin remained virtually the same

76 Carbapenems such as meropenem are being investigated for their potential the

77 vel for the experimental evidence indicating meropenem as a compound strongly affected by MexB contra

78 at 1000 mg every 8 h 3-h infusion, 77%, 83%; meropenem at 2000 mg every 8 hrs 3-hr infusion, 87%, 94%

79 00 mg every 6 hrs 0.5-hr infusion, 62%, 69%; meropenem at 500 mg every 6 hrs 0.5-hr infusion, 67%, 76

80 a were proposed for cefotaxime, ceftriaxone, meropenem, azithromycin, and minocycline.

81 Fluorescein-meropenem binds both penicillin-binding proteins and bet

82 veral of our new carbapenems are superior to meropenem both with respect to the efficiency of in vitr

83 ngs that also identified two populations for meropenem bound in SHV-1: one with the acyl CO group in

84 ompared to the structure of the same ring in meropenem bound to OXA-13.

85 Control and Prevention against imipenem and meropenem by agar dilution, disk diffusion, Etest (AB BI

86 is study, we show the utility of fluorescein-meropenem by using it to detect mutants of OXA-24/40 tha

87 h intravenous infusion every 8 h) or 1000 mg meropenem (by 30-min intravenous infusion every 8 h) for

88 ly sampled preterm infants demonstrates that meropenem, cefotaxime and ticarcillin-clavulanate are as

89 idpoint, or trough plasma concentrations for meropenem, ceftolozane-tazobactam, and ceftazidime-aviba

90 nt in blood culture (BC) bottles in removing meropenem, ceftolozane-tazobactam, and ceftazidime-aviba

91 ntly inactivate achievable concentrations of meropenem, ceftolozane-tazobactam, and ceftazidime-aviba

92 Teicoplanin combined with meropenem, ciprofloxacin, or moxifloxacin was also predo

93 The meropenem/ciprofloxacin combination gave the lowest mean

94 Recently, meropenem-clavulanate was shown to be effective against

95 Meropenem concentrations were measured by high-performan

96 e-dimensional structure of the covalent BlaC-meropenem covalent complex at 1.8 angstrom resolution.

97 of a MacConkey agar plate on which a 10-mug meropenem disk was placed and plating on MacConkey agar

98 ured to a MacConkey agar plate with a 10-mug meropenem disk) and for sequencing of DNA obtained from

99 ion testing was performed with 10-micrograms meropenem disks from two manufacturers.

100 The performance of both meropenem disks was comparable and considered acceptable

101 The imipenem, meropenem, doripenem, and ertapenem MIC50 values were 4,

102 Patients received a meropenem dose of 1 g iv every 12 hrs as a 5-min bolus.

103 A meropenem dose of 1g iv every 12 hrs provides adequate s

104 ted through 3 and 30 days following the last meropenem dose, respectively.

105 MIC values of meropenem, doxycycline, ceftazidime, and ceftriaxone for

106 riconazole due to the Aspergillus flavus and meropenem due to the Pseudomonas aeruginosa was initiate

107 . aeruginosa was tested against imipenem and meropenem, except for Vitek testing (major error rate fo

108 or patients receiving cefepime compared with meropenem for invasive infections caused by organisms ex

109 e of reference BMD or Etest for cefepime and meropenem for susceptibility testing of KPC-producing K.

110 cefotaxime (from 10 percent to 15 percent), meropenem (from 10 percent to 16 percent), erythromycin

111 otics that have varying mechanisms of action-meropenem, gentamicin, and ceftazidime-highlighting the

112 oup, compared with 211 (78.1%) of 270 in the meropenem group (difference -0.7% [95% CI -7.9 to 6.4]).

113 ared with 270 (73.0%) of 370 patients in the meropenem group (difference -4.2% [95% CI -10.8 to 2.5])

114 ibactam group versus 299 (74%) of 403 in the meropenem group (safety population), and were mostly mil

115 all mortality rate was 20% (10 of 50) in the meropenem group and 18% (9 of 50) in the placebo group (

116 eveloped in 18% (9 of 50) of patients in the meropenem group compared with 12% (6 of 50) in the place

117 avibactam group and 54 (13%) patients in the meropenem group.

118 eftolozane/tazobactam plus metronidazole and meropenem groups, respectively, and 100% (13/13) and 72.

119 According to our results, meropenem has a higher affinity to the distal binding po

120 sess in vitro susceptibility to carbapenems (meropenem, imipenem) by MIC and disk diffusion methods a

121 1 beta-lactamase enzyme and the carbapenems, meropenem, imipenem, and ertapenem, have been studied by

122 Meropenem, imipenem, cefepime, ceftazidime (2 g every 8

123 h Enterobacteriaceae infections treated with meropenem, imipenem, or doripenem.

124 following antimicrobials at standard doses: meropenem, imipenem-cilastatin, ceftazidime, cefepime, p

125 bactam plus metronidazole were compared with meropenem in 1066 men and women with complicated intra-a

126 ntilator-associated pneumonia, compared with meropenem in a multinational, phase 3, double-blind, non

127 results, in vivo studies using ertapenem and meropenem in a rabbit model of P. acnes endophthalmitis

128 bactam plus metronidazole was noninferior to meropenem in adult patients with cIAI, including infecti

129 emonstrated that hydrolytic decomposition of meropenem in living Escherichia coli cells carrying New

130 ceftazidime-avibactam plus metronidazole to meropenem in the microbiologically modified intention-to

131 bactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/389] vs 87.3% [364/

132 bactam plus metronidazole was noninferior to meropenem in the treatment of complicated intra-abdomina

133 N: Ceftazidime-avibactam was non-inferior to meropenem in the treatment of nosocomial pneumonia.

134 cetic acid (EDTA), inhibit the hydrolysis of meropenem in vivo.

135 to determine the safety and effectiveness of meropenem in young infants with suspected or complicated

136 e D,D-carboxypeptidase DacB2 and showed that meropenem indeed directly inhibits this enzyme by formin

137 Imipenem and meropenem induced faster killing of E. coli than ceftria

138 e in the tetrapeptide pools, suggesting that meropenem inhibits both a D,D-carboxypeptidase and an L,

139 c decomposition of the carbapenem antibiotic meropenem inside Escherichia coli cells expressing New D

140 Meropenem is a broad-spectrum antimicrobial with excelle

141 Meropenem is an extremely slow substrate for BlaC and ex

142 Meropenem is approved for use in children, cefepime is a

143 Meropenem is closely related to imipenem and was recentl

144 Meropenem is well tolerated and more efficacious than th

145 ts were determined to be possibly related to meropenem (isolated ileal perforation and an episode of

146 erved [minimum inhibitory concentration (MIC(meropenem)) less than 1 microgram per milliliter], and s

147 re endemic, testing for nonsusceptibility to meropenem may provide improved accuracy in identifying t

148 racillin-tazobactam (PT), cefepime (CE), and meropenem (ME).

149 f two zwitterionic carbapenems, imipenem and meropenem, measured using liposome permeation assays and

150 tions]) and the beta-lactams imipenem (IPM), meropenem (MEM), ertapenem (ERT), and ceftazidime (CAZ).

151 Imipenem (IPM), meropenem (MEM), ertapenem (ERT), and doripenem (DOR) we

152 ts, and the majority of infants treated with meropenem met the definition of therapeutic success.

153 d MicroScan methods to accurately define the meropenem MIC and categorical interpretation of suscepti

154 Meropenem MIC results and categorical interpretations fo

155 resistant to imipenem (MIC, >256 mug/ml) and meropenem (MIC, 128 mug/ml) and belonged to ST3835.

156 non-CP-CRE isolates were more likely to have meropenem MICs </=1 microg/mL (P value < .001).

157 CP-CRE isolates were more likely to have meropenem minimum inhibitory concentrations (MICs) >/=16

158 stant infections was comparable to that with meropenem (mMITT population, 83.0% and 85.9%, respective

159 After clinical deterioration using meropenem monotherapy, treatment success was achieved af

160 Susceptibility to ceftazidime and meropenem occurred in approximately 70% of the isolates.

161 ignificantly less IL-6 release compared with meropenem or ceftriaxone.

162 When meropenem or ertapenem was reacted with SHV-1 in solutio

163 nteractors of Oxa-23 demonstrates changes in meropenem or imipenem sensitivity in strain AB5075.

164 class currently being prescribed (cefepime, meropenem, or piperacillin-tazobactam) or had a positive

165 ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penicillin (PEN), tetracycline (TET), trimeth

166 taxime, ceftriaxone, doxycycline, linezolid, meropenem, penicillin, rifampin, tetracycline, trimethop

167 Minocycline, imipenem, meropenem, piperacillin, and piperacillin-tazobactam wer

168 articles describing the pharmacokinetics of meropenem, piperacillin, and vancomycin in critically il

169 of the patient groups involved in studies of meropenem, piperacillin, and vancomycin were 55.3, 60.3,

170 Other antibiotics, such as meropenem, piperacillin/tazobactam, and cefuroxime, were

171 The combination of meropenem plus daptomycin is more effective than ceftazi

172 The aim of our study was to compare meropenem plus daptomycin versus ceftazidime in the trea

173 The combination of meropenem plus daptomycin was significantly more effecti

174 Meropenem plus levofloxacin treatment was shown to be a

175 The combination of meropenem plus levofloxacin was synergistic, producing g

176 tified resistance to cefepime, resistance to meropenem, presence of multidrug resistance, nonabdomina

177 We were able to predict the Meropenem resistance of these bacteria on the basis of t

178 CR revealed that imipenem resistance but not meropenem resistance was associated with the presence of

179 the presence of bla(KPC) in an additional 20 meropenem-resistant isolates from 16 patients.

180 Seven imipenem-resistant and five meropenem-resistant isolates of Enterobacteriaceae and 4

181 acteriaceae and 43 imipenem-resistant and 21 meropenem-resistant isolates of P. aeruginosa were ident

182 ) in all of the reference strains, in 6 of 7 meropenem-resistant isolates, and in 0 of 62 meropenem-s

183 onfirm the presence of bla(KPC) genes in any meropenem-resistant Klebsiella spp.

184 ceftazidime-avibactam plus metronidazole and meropenem, respectively, were as follows: mMITT populati

185 susceptible, intermediate, and resistant to meropenem, respectively.

186 actamase inhibitor clavulanate together with meropenem resulted in rapid, polar, cell lysis releasing

187 e enzyme, and its reaction with imipenem and meropenem revealed biphasic fluorescence time courses wi

188 SKIE determinations with meropenem revealed large SKIEs on both the acylation and

189 ent therapy and extracorporeal clearance for meropenem (rs = 0.43; p = 0.12), piperacillin (rs = 0.77

190 The crystal structure of NDM-1 bound to meropenem shows for the first time the molecular details

191 of cytochrome P450 (CYP) 2C19 and CYP3A4 by meropenem, suggesting that during meropenem treatment, n

192 were inoculated with one of two isolates (1 meropenem susceptible and 1 resistant), followed by fres

193 meropenem-resistant isolates, and in 0 of 62 meropenem-susceptible clinical isolates.

194 For Enterobacteriaceae, the imipenem and meropenem test methods produced low numbers of very majo

195 For both cefaclor and meropenem, the rate-determining step for hydrolysis is l

196 outcomes for patients receiving cefepime or meropenem therapy were compared.

197 loxacin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole

198 hese results suggest that the rapid lysis of meropenem-treated cells is the result of synergistically

199 Sixty-three meropenem-treated patients and 58 ceftazidime-tobramycin

200 responses occurred in 56 (89%) of 63 of the meropenem-treated patients and in 42 (72%) of 58 of the

201 Seizures were reported in three meropenem-treated patients, but these seizures were cons

202 Meropenem treatment was accompanied by a dramatic accumu

203 CYP3A4 by meropenem, suggesting that during meropenem treatment, narrow therapeutic index drugs meta

204 es in the binding properties of imipenem and meropenem, two potent antibiotics of the carbapenem fami

205 urther validated by determining the relative meropenem uptake by Pseudomonas aeruginosa wild-type ver

206 tile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8-18.4), 105.0 (74.4-204.0)/3.8 (3

207 iconazole dose reductions whenever high-dose meropenem was added.

208 a combination of tigecycline, colistin, and meropenem was associated with lower mortality (OR: 0.11;

209 When meropenem was combined with the beta-lactamase inhibitor

210 Meropenem was highly active against H. influenzae strain

211 ibiotic therapy comprising metronidazole and meropenem was partly beneficial in improving the patient

212 In both systems, meropenem was removed to a greater degree than were ceft

213 Bacterial resistant to levofloxacin and meropenem was seen in the control arm.

214 Meropenem was well tolerated in this cohort of criticall

215 A rigid carbapenem (meropenem) was most affected by the Asn276Asp substituti

216 By reacting fluorescein isothiocyanate with meropenem, we have prepared a carbapenem-based fluoresce

217 r piperacillin, piperacillin-tazobactam, and meropenem were <0.80.

218 es of Trypticase soy broth plus ertapenem or meropenem were 78% and 47%, respectively.

219 , and vancomycin; minocycline, imipenem, and meropenem were also highly active (>92% susceptibility).

220 llin-tazobactam, ticarcillin-clavulanate, or meropenem were randomized to receive the prescribed anti

221 ciprofloxacin paired with either imipenem or meropenem were the most active combinations and inhibite

222 bramycin, and only one major (M) error, with meropenem, when DD results were compared with BMD result

223 1% between penicillins and both imipenem and meropenem, whereas a single study found a cross-reactivi

224 ty between penicillins and both imipenem and meropenem, while a single study found a 5.5% rate of cro

225 eta-lactams of the carbapenem class, such as meropenem, with clavulanate, a beta-lactamase inhibitor,

226 2 microg/ml) were identified as part of the Meropenem Yearly Susceptibility Test Information Collect

227 -positive organisms treated with cefepime or meropenem yielded 32 well-balanced patient pairs with no